Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic riskJill Corre, Hervé Avet‐Loiseau, Denis Caillot et al.|Haematologica|2019Cited by 90
A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated ResultsMurielle Roussel, Arnaud Jaccard, Bertrand Arnulf et al.|Clinical Lymphoma Myeloma & Leukemia|2019Cited by 6